

Registration, Students and Bursaries

Registration is open, and discounted rates are offered to RSC and SCI student members. The RSC and SCI are also offering some student bursaries. Registration fees include:

- gratis coach transport between Verona city centre and the Evotec campus at the start and end of each day
- dinner on Wednesday evening at the Ristorante Scaligero
- vineyard visit and dinner on Thursday evening at Rocca Sveva.

Early registration fees, for payment by 4th July:

£500 Member of the RSC or SCI

£700 Non-member

£200 Student member, unemployed member, retired member

£300 Student non-member, unemployed non-member, retired non-member

Venue, Travel and Accommodation

Venue: Evotec Campus Levi-Montalcini, Verona, Italy

Travel: Detailed travel information may be found on the website.

Accommodation: Verona Booking is offering a hotel booking service.

Sponsors


We are grateful to Evotec for their generous support of this event. Additional sponsors would be welcomed.



evotec



THE SCIENCE of POSSIBILITY



Organising Committee

Daniele Andreotti, Evotec, IT
Adrian Hall (co-chairman), UCB, BE
Duncan Hay (treasurer), Vertex, UK
Caroline Low (co-chairman),
Isomorphic Laboratories, UK
Nigel Swain, Sosei Heptares, UK

Secretariat Contact

For further information, please contact the event secretariat: Maggi Churchouse,
maggi.churchouse@rscbmcs.org

Website: <https://www.rscbmcs.org>


Also www.rsc.org/bmcs and www.soci.org/events

Exhibitor Opportunities

Please see our website for information about exhibitor opportunities.



Second announcement and call for posters



8th RSC / SCI Symposium on GPCRs in Medicinal Chemistry

Wednesday-Friday, 5th-7th October 2022

Evotec Campus Levi-Montalcini
Verona, Italy

Organised by:
RSC Biological and Medicinal Chemistry Sector and
SCI Fine Chemicals Group



Synopsis

The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to be holding this 8th meeting in the series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

Features of the Meeting

- Case studies in GPCR drug discovery and development
- Structural biology advances and impact on drug design
- Showcasing multiple modalities and drug discovery approaches to modulating GPCRs

Also: poster session - trade exhibition opportunities - two evening dinners and vineyard visit - accommodation agency booking service.

Call for Posters

Abstracts are invited for poster presentations. Applicants have the opportunity to provide a short flash oral presentation. The closing date is 11th August, and several prizes will be awarded. The call for oral abstracts closed on 31st March.

Programme Timings

To assist you with your travel plans, expected start and finish times are:

- Day 1 08.30 Registration opens
- Day 1 09.20 Technical programme starts
- Day 3 15.00 Close of symposium

Confirmed Speakers

Discovery of VU6028418: a highly selective and orally bioavailable M4 muscarinic acetylcholine receptor antagonist

Aaron Bender, Vanderbilt University, US

Discovery of the clinical candidate ACT-777991, a potent CXCR3 antagonist with therapeutic potential in autoimmune diseases

Eva Caroff, Idorsia, CH

Understanding allostery at GPCRs

Keynote: **Arthur Christopoulos**, Monash University, AU

AlphaFold and GPCRs (provisional title)

Miles Congreve and Caroline Low, Isomorphic Laboratories, UK

Impact of GPCR structure-based drug discovery on identification and optimisation of allosteric modulators that bind at the receptor-membrane interface

Anna Cooper, Sosei Heptares, UK

The discovery of CFTX-1554 as an inhibitor of the angiotensin II type 2 receptor, a clinically validated target for the treatment of neuropathic pain

Ann De Blieck, Confo Therapeutics, BE

Confirmed Speakers (continued)

Structure-based drug discovery across the medicinal chemical GPCRome

Chris de Graaf, Sosei Heptares, UK

The resolution revolution: GPCR structure-based drug design in 20:20 vision (in 2022)

James Errey, Evotec, UK

Identification of H4R antagonist HTL0032547 as a potential therapy for atopic dermatitis

Charlotte Fieldhouse, Sosei Heptares, UK

Roadmap and resource for GPCR biased signalling

Keynote: **David Gloriam**, University of Copenhagen, DK (virtual)

Discovery of AZD5462, an oral agonist of the Relaxin family peptide receptor 1 (RXFP1) for the treatment of cardiorenal disease

Kenneth Granberg, AstraZeneca, SE

Discovery of potent and selective S1P2 receptor antagonists for treatment of idiopathic pulmonary fibrosis

Bertrand Heckmann, Galapagos, FR

GPCR-based drug design with fragment molecular orbital method

Alexander Heifetz, Evotec, UK

Discovery of MK-4710: a potent, selective, and bioavailable M4 positive allosteric modulator

Michael Lo, MSD, US (virtual)

Salipro DirectMX® enables discovery of novel therapeutics against GPCRs

Robin Löving, Salipro, SE

Structure-guided GPCR drug discovery

Keynote: **Bryan Roth**, Eshelman School of Pharmacy, University of North Carolina, USA

How to leverage new AI technologies alongside traditional HTS to better validate hit compounds for GPCRs

Carleton Sage, Eurofins Discovery, US

Discovery of Pecavaptan: a novel dual acting vasopressin

V1a/V2 receptor antagonist for the treatment of worsening chronic heart failure

Carsten Schmeck, Bayer, DE

Discovery of FPR2 agonists for treatment of heart failure

Nicholas Wurtz, Bristol-Myers Squibb, US



Website: <https://www.rscbmcs.org>

Also www.rsc.org/bmcs and www.soci.org/events